Currently, there are 492.85M common shares owned by the public and among those 488.17M shares have been available to trade.
The company’s stock has a 5-day price change of -10.67% and -9.85% over the past three months. ELAN shares are trading -8.46% year to date (YTD), with the 12-month market performance up to 46.98% higher. It has a 12-month low price of $7.88 and touched a high of $16.88 over the same period. ELAN has an average intraday trading volume of 4.16 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -12.14%, -13.77%, and 5.51% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Elanco Animal Health Inc (NYSE: ELAN) shares accounts for 98.35% of the company’s 492.85M shares outstanding.
It has a market capitalization of $6.72B and a beta (3y monthly) value of 1.33. The earnings-per-share (ttm) stands at -$2.50. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.37% over the week and 2.57% over the month.
Analysts forecast that Elanco Animal Health Inc (ELAN) will achieve an EPS of $EJAN for the current quarter, $27.04 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Eledon Pharmaceuticals, Inc. while analysts give the company a high EPS estimate of $Enliven Therapeutics, Inc.. Comparatively, EPS for the current quarter was $eGain Corporation a year ago. Earnings per share for the fiscal year are expected to increase by 3.52%, and 15.07% over the next financial year.
Looking at the support for the ELAN, a number of firms have released research notes about the stock. Stifel stated their Buy rating for the stock in a research note on January 05, 2024, with the firm’s price target at $13-$20. Jefferies coverage for the Elanco Animal Health Inc (ELAN) stock in a research note released on December 19, 2023 offered a Buy rating with a price target of $17. Morgan Stanley was of a view on December 15, 2023 that the stock is Overweight, while Exane BNP Paribas gave the stock Outperform rating on December 07, 2023, issuing a price target of $18. Barclays on their part issued Overweight rating on April 20, 2023.
